206 related articles for article (PubMed ID: 27100303)
21. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
22. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.
Holme PA; Glomstein A; Grønhaug S; Tjønnfjord GE
Haemophilia; 2009 May; 15(3):727-32. PubMed ID: 19320748
[TBL] [Abstract][Full Text] [Related]
23. On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.
Sørensen B; Dargaud Y; Kenet G; Lusher J; Mumford A; Pipe S; Tiede A
Haemophilia; 2012 Mar; 18(2):255-62. PubMed ID: 21771206
[TBL] [Abstract][Full Text] [Related]
24. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.
Kavakli K; Makris M; Zulfikar B; Erhardtsen E; Abrams ZS; Kenet G;
Thromb Haemost; 2006 Apr; 95(4):600-5. PubMed ID: 16601828
[TBL] [Abstract][Full Text] [Related]
25. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.
Hoots WK; Ebbesen LS; Konkle BA; Auerswald GK; Roberts HR; Weatherall J; Ferran JM; Ljung RC;
Haemophilia; 2008 May; 14(3):466-75. PubMed ID: 18282155
[TBL] [Abstract][Full Text] [Related]
26. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
Gringeri A; Fischer K; Karafoulidou A; Klamroth R; López-Fernández MF; Mancuso E;
Haemophilia; 2011 Jul; 17(4):630-5. PubMed ID: 21323801
[TBL] [Abstract][Full Text] [Related]
27. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE).
Valentino LA; Walsh CE; Reding MT; Young GA; Levendoglu-Tugal O; Cooper DL
Haemophilia; 2012 Jul; 18(4):554-60. PubMed ID: 22348407
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
Thromb Res; 2014 Feb; 133(2):162-7. PubMed ID: 24321420
[TBL] [Abstract][Full Text] [Related]
29. Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors.
Polyanskaya T; Zorenko V; Karpov E; Sampiev M; Mishin G; Vasiliev D
Haemophilia; 2012 Nov; 18(6):997-1002. PubMed ID: 22672066
[TBL] [Abstract][Full Text] [Related]
30. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
Nicolaisen EM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
[TBL] [Abstract][Full Text] [Related]
31. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia.
Tiede A; Worster A
Ann Hematol; 2018 Oct; 97(10):1889-1901. PubMed ID: 29804265
[TBL] [Abstract][Full Text] [Related]
32. Home treatment with recombinant activated factor VII: results from one centre.
Ingerslev J; Thykjaer H; Kudsk Jensen O; Fredberg U
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S107-10. PubMed ID: 9819039
[TBL] [Abstract][Full Text] [Related]
33. Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia.
Klamroth R; Gottstein S; Essers E; Landgraf H; Wilaschek M; Oldenburg J
Haemophilia; 2009 Jan; 15(1):247-52. PubMed ID: 18691374
[TBL] [Abstract][Full Text] [Related]
34. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
Qi X; Zhao Y; Li K; Fan L; Hua B
Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
[TBL] [Abstract][Full Text] [Related]
35. Early treatment with recombinant factor VIIa results in greater efficacy with less product.
Lusher JM
Eur J Haematol Suppl; 1998; 63():7-10. PubMed ID: 9882925
[TBL] [Abstract][Full Text] [Related]
36. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
Kavakli K; Demartis F; Karimi M; Eshghi P; Neme D; Chambost H; Sommer L; Zak M; Benson G
Haemophilia; 2017 Jul; 23(4):575-582. PubMed ID: 28440004
[TBL] [Abstract][Full Text] [Related]
37. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
Stewart AJ; Hanley JP; Ludlam CA
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
[TBL] [Abstract][Full Text] [Related]
38. Approaches towards successful home treatment in patients with inhibitors.
Ingerslev J; Thykjaer H; Scheibel E
Eur J Haematol Suppl; 1998; 63():11-4. PubMed ID: 9882926
[TBL] [Abstract][Full Text] [Related]
39. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
[TBL] [Abstract][Full Text] [Related]
40. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
Hay JW; Zhou ZY
Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
